SA News • Wed, Dec. 17
Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
- Trading at less than a quarter of valuation of its closest peer that was acquired by Roche in August 2014, Marina Biotech is extremely undervalued.
- News in the RNA therapeutics sector continues to attract strong attention; most recently in Regulus Therapeutics’ Phase I Hepatitis-C results.
- Marina overcame immediate cash concerns and regained SEC compliance following a February 2014 $6M financing from Tekmira investor Steven Newby, which piqued our interest leading to this detailed review.
- Marina still needs more cash to achieve its goals, but has a good chance of funding itself via partnership or more financing at higher levels due to extremely strong IP.
- After carefully reviewing Marina's promising technologies and competitive position, we value the company at $4.50 per share.
There are no Transcripts on MRNA.
Wed, Dec. 17, 10:10 AM
- Pfizer (PFE +0.2%) initiates a Phase 2 clinical trial assessing its investigational compound, PF-06252616, in boys with Duchenne Muscular Dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. It occurs in ~1 in 3,500 male births worldwide.
- The study will evaluate the safety, tolerability and efficacy of PF-06252616 in boys aged 6 to <10 years old diagnosed with DMD regardless of genotype.
- The FDA designated PF-06252616 an Orphan Drug in July 2012 and Fast Track in November 2012.
- DMD-related tickers: (SRPT +4.1%)(RNA +0.1%)(PTCT +1.6%)(OTCQB:MRNA +5.8%)(ROSG +0.4%)
- Previously: Catabasis Pharmaceuticals' CAT-1004 tagged an Orphan Drug for DMD (Nov. 24, 2014)
Mon, Nov. 24, 12:15 PM
- The FDA designates privately-held Catabasis Pharmaceuticals' investigational NF-kB inhibitor, CAT-1004, an Orphan Drug for the treatment of Duchenne muscular dystrophy (DMD).
- NF-kB is a key mediator of cellular injury. Evidence suggests that activated NF-kB contributes to the underlying pathology of DMD.
- In a Phase 1 trial, CAT-1004 was well-tolerated and demonstrated a significant reduction of activated NF-kB. The company plans to proceed to Phase 2 development in 1H 2015.
- Among the benefits of Orphan Drug designation is a seven-year period of market exclusivity if approved.
- DMD-related tickers: (SRPT +7.6%)(RNA +63.3%)(BMRN +1.7%)(PTCT +3.4%)(OTCQB:MRNA -3.3%)(ROSG +0.8%)
Thu, Oct. 16, 3:37 PM
- Prosensa Holding N.V. (RNA +5.5%) commences its NDA submission process with the FDA for drisapersen for the treatment of Duchenne muscular dystrophy (DMD). The agency will review the application on a rolling basis as stipulated under Fast Track. It also designated drisapersen an Orphan Drug in June 2013.
- DMD-related tickers: (SRPT +7.1%)(PTCT +1.3%)(ROSG +8%)(OTCQB:MRNA)
Wed, Apr. 2, 9:26 AM
- Pico caps Rosetta Genomics (ROSG) and Marina Biotech (MRNA) establish a strategic collaboration to identify and develop microRNA-based products targeting neuromuscular diseases and dystrophies.
- Initial focus will be Becker and Duchenne muscular dystrophies and myotonic dystrophy.
- Rosetta will identify microRNAs associated with the diseases and, if correlative, will develop the diagnostic products. Marina will develop the therapeutics.
Mon, Mar. 31, 12:47 PM
Tue, Mar. 11, 12:47 PM
Wed, Feb. 26, 12:46 PM
Mon, Feb. 24, 12:48 PM
MRNA vs. ETF Alternatives
Other News & PR